Cardiac diseases in AIDS prevention

Cardiac diseases in AIDS Microchapters
Home
Overview
Pathophysiology
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
Echocardiography
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Cardiac diseases in AIDS prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
slides
Images
American Roentgen Ray Society Images of Cardiac diseases in AIDS prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Cardiac diseases in AIDS prevention
CDC on Cardiac diseases in AIDS prevention
Cardiac diseases in AIDS prevention in the news
Blogs on Cardiac diseases in AIDS prevention
Directions to Hospitals Treating Cardiac diseases in AIDS
Risk calculators and risk factors for Cardiac diseases in AIDS prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2]

Overview

Statins and aspirin have shown to reduce mortality from CVD in general population, but their use in HIV infected population is uncertain.

Prevention

• Various studies showed reduced mortality from CVD in HIV infected patients, but this effect was not found to be statistically significant. Statins are well tolerated in HIV infected populations, except for some side effects like myalgia and myopathies.
• Use of aspirin has certainly reduced mortality in general population, but its use in HIV infected patients has not been implicated. Results from CVD prevention trials in HIV infected patients are needed.

References

Template:WikiDoc Sources CME Category::Cardiology